SITC 2018 Support • General Information

The Society for Immunotherapy of Cancer's (SITC) Annual Meeting & Pre-Conference Programs attendance has nearly tripled in the past four years as the field continues to grow. We estimate that the 2018 attendance will exceed 4,000.

The SITC 2017 Annual Meeting & Pre-Conference Programs drew a record 3,632 attendees, representing a variety of countries, disease states and specialties coming together to advance the field of cancer immunotherapy.

Countries Represented

  • Australia
  • Austria
  • Belgium
  • Brazil
  • Canada
  • China, People's Republic of
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Hungary
  • India
  • Ireland
  • Israel
  • Italy
  • Japan
  • Korea, Republic of
  • Lebanon
  • Monaco
  • Netherlands
  • New Zealand
  • Norway
  • Philippines
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • Singapore
  • Slovania
  • Spain
  • Sweden
  • Switzerland
  • Taiwan
  • United Kingdom
  • United States

By Disease State

  • Lung - 31%
  • Melanoma - 28%
  • Pan-Tumor - 21%
  • Breast - 19%
  • Hematologic Malignancies - 18%
  • Other - 18%
  • Gastrointestinal - 14%
  • Head & Neck - 14%
  • Prostate - 10%
  • Bladder - 9%
  • Renal - 7%
  • Liver - 7%
  • Brain/Central Nervous System - 7%
  • Gynecological - 5%
  • Neuroblastoma - 3%

By Specialty

2017 Attendees by Specialty
Immunology/Immunotherapy
Medical Oncology
Clinical Investigations/Clinical Trials
Cellular Biology
 Biochemistry
Hematology
Genetics and Genomics
Molecular Biology
Other
Sondel.jpg
Session_Breakout_Table.jpg